Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholinergic therapy in dementia

P J Whitehouse1

  • 1Alzheimer Center, University Hospitals of Cleveland, Case Western Reserve University, Ohio 44106.

Acta Neurologica Scandinavica. Supplementum
|January 1, 1993
PubMed
Summary

This review examines cholinomimetic drugs for dementia treatment, focusing on cholinesterase inhibitors like tacrine. Newer drugs targeting cholinergic receptors may offer improved effectiveness for Alzheimer's disease and related disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethical issues in dementia.

Dialogues in clinical neuroscience·2011
Same author

The role of nutrients in the prevention and treatment of Alzheimer's disease: methodology for a systematic review.

European journal of neurology·2009
Same author

Speaking of research advance directives: planning for future research participation.

Neurology·2006
Same author

Twenty-four-hour rhythms of sleep-wake cycle and temperature in Alzheimer's disease.

The Journal of neuropsychiatry and clinical neurosciences·2004
Same author

Donepezil.

Drugs of today (Barcelona, Spain : 1998)·2004
Same author

Paying attention to acetylcholine: the key to wisdom and quality of life?

Progress in brain research·2003

Area of Science:

  • Neuroscience
  • Pharmacology
  • Geriatrics

Background:

  • Alzheimer's disease (AD) and related dementias exhibit significant cholinergic pathology.
  • Current treatments aim to address neurotransmitter deficits.

Purpose of the Study:

  • To review evidence for cholinergic pathology in dementia.
  • To evaluate cholinomimetic drug strategies for dementia treatment.
  • To discuss emerging therapies for Alzheimer's disease.

Main Methods:

  • Literature review of studies on cholinergic pathways in dementia.
  • Analysis of clinical trial data for cholinomimetic drugs.
  • Examination of FDA-approved treatments and investigational agents.

Main Results:

  • Cholinesterase inhibitors, such as tacrine, are established treatments.
  • Drugs targeting muscarinic and nicotinic cholinergic receptors show promise for enhanced efficacy.
  • Strategies for disease progression modification are under investigation.

Conclusions:

  • Cholinomimetic drugs represent a key therapeutic avenue for dementia.
  • Further research into novel cholinergic receptor modulators is warranted.
  • Comprehensive treatment strategies may include disease-modifying approaches.

Related Experiment Videos